In this SOHO Insider interview, Pearl van Heteren, MD, medical director in clinical development (Europe) at Miltenyi Biomedicine, discusses the primary analysis of the DALY 2-EU trial in patients with relapsed or refractory diffuse large B-cell lymphoma.
The trial investigators are comparing zamtocabtagene autoleucel (zamto-cel), a CAR-T cell therapy, with the standard of care as second-line therapy in nontransplant eligible patients with relapsed or refractory DLBCL. Dr. van Heteran discusses early efficacy and safety signals of zamto-cel and the therapy’s rapid manufacturing time.
The trial is being conducted in twelve sites across Europe.
Reference
Borchmann P, Van Meerten T, Bories P. Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study. Abstract #669. Presented at the 2025 American Society of Hematology Annual Meeting. December 6–9; Orlando, FL.
